CAJ | 학술논문

目的：评价艾迪注射液联合顺铂胸腔灌注治疗癌性胸腔积液的有效性及其安全性。方法采用Cochrane系统评价方法，检索Pubmed、EMBASE、中国期刊全文数据库、万方科技期刊全文数据库、维普中文科技期刊数据库，同时联合其他检索方法，纳入符合标准的随机对照试验，使用RevMan5．0软件进行Meta分析。结果共纳入9项研究（n＝549），结果显示艾迪注射液联合顺铂的方案与单独使用顺铂的方案治疗癌性胸腔积液的胸水减少率（OR：3．13，95％CI：2．14～4．57，P＜0．00001）与患者生活质量（OR：2．96，95％CI：2．04～4．30，P＜0．00001）的差异有统计学意义，且艾迪注射液联合顺铂治疗组的不良反应中血液系统毒性，消化系统毒性及胸痛与单纯使用顺铂组相比明显下降（P＜0．00001）。结论艾迪注射液与顺铂联合使用治疗患者的癌性胸腔积液疗效确切，安全性也得到了提高。
목적：평개애적주사액연합순박흉강관주치료암성흉강적액적유효성급기안전성。방법채용Cochrane계통평개방법，검색Pubmed、EMBASE、중국기간전문수거고、만방과기기간전문수거고、유보중문과기기간수거고，동시연합기타검색방법，납입부합표준적수궤대조시험，사용RevMan5．0연건진행Meta분석。결과공납입9항연구（n＝549），결과현시애적주사액연합순박적방안여단독사용순박적방안치료암성흉강적액적흉수감소솔（OR：3．13，95％CI：2．14～4．57，P＜0．00001）여환자생활질량（OR：2．96，95％CI：2．04～4．30，P＜0．00001）적차이유통계학의의，차애적주사액연합순박치료조적불량반응중혈액계통독성，소화계통독성급흉통여단순사용순박조상비명현하강（P＜0．00001）。결론애적주사액여순박연합사용치료환자적암성흉강적액료효학절，안전성야득도료제고。
Objective To evaluate the effectiveness and safety of carcinogenic pleural effusion trea-ted with Aidi Injection plus Cisplatin.Methods Cochrane systematic evaluation method was adopted. Pubmed,EMBASE,CNKI,Wanfag Data,VIP and others were used for retrieval.The randomized controlled trial in accordance with the standard was included.RevMan 5 .0 software was used for Meta analysis.Results Nine projects were included(n=549).The results showed that the decrement rate of hydrothorax(OR:3.1 3, 95%CI:2.1 4 to 4.57,P<0.000 01 )in carcinogenic pleural effusion and the patient′s life quality(OR:2.96,95%CI:2.04 to 4.30,P<0.000 01 )were different significantly between the allied program of Aidi In-jection and Cisplatin and the simple application of Cisplatin.Regarding the adverse reaction,hematologic tox-icity,digestive toxicity and chest pain in the allied program of Aidi Injection and Cisplatin were apparently re-duced as compared with the simple application of Cisplatin(P<0.000 01 ).Conclusion The allied program of Aidi Injection and Cisplatin achieves definite efficacy on carcinogenic pleural effusion and improves the safety of treatment.